Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Inclusion Criteria: * Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria (Trautinger et al, Eur J Cancer, 2017) * Age ≥18 years * Have failed at least one previous line of systemic therapy * Have received mogamulizumab in real life setting after the approval and reimbursement of the drug from the National Health System in December 2020 * Have received first dose of mogamulizumab between 01/01/2021 and 31/01/2023 * Have received mogamulizumab at the standard approved dose (1.0 mg/kg intravenously on days 1, 8, 15 and 22 of the first cycle and on days 1 and 15 of subsequent cycles) * Availability of complete medical records. Exclusion Criteria: • Patients not meeting the above-mentioned inclusion criteria